Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
Focus of Report: This report focuses on the use of the NightBalance sleep position trainer (SPT) system for treatment of positional obstructive sleep apnea (POSA).
Technology Description: The NightBalance consists of a palm-sized device that is worn across the chest using an adjustable…
Oleogel-S10 is a semisolid gel containing 10% betulin-rich extract from birch bark and 90% refined sunflower oil. Betulin is a naturally occurring triterpene with medicinal properties believed to help modulate the inflammation response and encourage formation of new skin during wound healing. It is in development for the treatment of skin wounds associated with epidermolysis …
Embozene Microspheres are biocompatible, nonresorbable hydrogel particles under investigation for genicular artery embolization (GAE) to treat symptomatic knee osteoarthritis (OA).
This report evaluates the clinical utility of pharmacogenomic testing to inform the selection or dose of medications for individuals diagnosed with depression, bipolar disorder, schizophrenia spectrum or other psychotic disorder, or anxiety disorder to improve clinical outcomes.
Focus of the Report: The focus of this report is on allogeneic hematopoietic stem cell transplantation (HSCT) utilizing alternative human leukocyte antigen (HLA)-matched donor sources in pediatric patients with sickle cell disease (SCD) without an HLA-matched sibling donor (MSD).
Technology D…
Aduhelm (aducanumab) is an intravenously administered amyloid beta-directed antibody for the treatment of Alzheimer disease.
Focus of the Report: This health technology assessment focuses on the efficacy and safety of the life under kinetic evolution (LUKE) arm (Mobius Bionics) for adults with upper extremity (or limb) amputation.
Technology Description: Developed by DEKA Research and Development Corporation…
Beta thalassemia is blood disorder caused by sequent variants in the beta-globin (HBB) gene that threaten normal production of hemoglobin. Lentiviral Autologous Beta-Globin Gene Therapy (Proposed Name: Zynteglo, formerly LentiGlobin) aims to reduce or eliminate the need for regular blood transfusions in patients with transfusion-dependent beta-t…
Vosoritide is a longer-acting C-type natriuretic peptide (CNP) analog that modulates activity of the fibroblast growth factor receptor 3 (FGFR3) by inhibiting a signaling pathway that mediates its effects, thereby stimulating endochondrial growth, resulting in enhanced growth velocity. It is indicated to increase linear growth in pediatric patients aged ≥ 5 years with achondr…
Mavacamten is an investigational oral myosin inhibitor that targets the underlying molecular mechanisms of hypertrophic cardiomyopathy (HCM). It is proposed for the treatment of patients with symptomatic obstructive HCM.